• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home The Classics Hematology/Oncology Classics

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

byDeepti Shroff, DMD, MS
September 16, 2022
in Hematology/Oncology Classics, Obstetrics and Gynecology Classics, The Classics
Reading Time: 3 mins read
Share on FacebookShare on TwitterShare on LinkedIn

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. Women with advanced-stage (≥Stage III) ovarian cancer randomized to intraperitoneal chemotherapy achieved an increase in overall survival compared to controls.

Original Date of Publication: January 2006

Study Rundown: Ovarian cancer is the most deadly gynecologic malignancy. Due to nonspecific presenting symptoms and disease predilection for early intraabdominal spread via peritoneal lymphatics, the majority of patients present with advanced-stage disease. As of the early 2000s, the standard of care for women with advanced disease involved optimal tumor reductive surgery, defined as resection of all disease > 1 cm, followed by adjuvant intravenous chemotherapy. The most common chemotherapy regimen involved 6 cycles of paclitaxel and a platinum analogue, such as cisplatin. The peritoneal cavity is the primary site of disease in ovarian cancer, which triggered researchers to postulate that applying chemotherapy locally to the peritoneal cavity might improve disease response and decrease toxicities associated with intravenous chemotherapy. Previous trials comparing intravenous only (IV) versus intravenous plus intraperitoneal (IV/IP) chemotherapy produced mixed results: one demonstrated a significant survival advantage in the IV/IP group while another showed an improvement in the progression-free interval but not survival.

This landmark Phase 3 clinical trial compared the standard of care, IV cisplatin/paclitaxel, to IV paclitaxel with IP cisplatin/paclitaxel and found that the IV/IP regimen was associated with increase in both progression-free survival and overall survival. However, the minority (< 50%) of patients in the IV/IP group completed 6 cycles of treatment due to toxicities including fatigue, pain and neurologic side effects. Findings changed clinical practice such that patients with advanced-stage ovarian cancer who seek to maximize survival at the cost of an increased risk of treatment-associated toxicities are now offered IP chemotherapy. Strengths included parsimonious, multicenter, randomized controlled trial through the Gynecologic Oncology Group (GOG). Central review of the complete medical record by GOG physician-scientists permitted adherence to strict inclusion and exclusion criteria. Findings are limited by a low completion rate of IV/IP regimen due to toxicities, which may bias results toward the null.

Click to read the study in the NEJM (New England Journal of Medicine)

EvidencePulse™by 2 Minute Medicine®

How does Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series] apply to your patient?

Describe your patient and EvidencePulse weighs this trial against later evidence and current guidelines, with citations.

Ask EvidencePulse

For a fuller review of the evidence, Deep research is a core feature of 2MM Max.

In-Depth [randomized controlled trial]: A total of 415 women with Stage III ovarian carcinoma or primary peritoneal carcinoma who underwent optimal tumor reductive surgery (no residual mass greater than 1.0cm) were randomized to receive intravenous cisplatin/paclitaxel (“IV,” n = 210) or intravenous paclitaxel followed by intraperitoneal cisplatin/paclitaxel (“IV/IP,” n = 205) for 6 cycles of chemotherapy occurring every three weeks at one of the Gynecologic Oncology Group (GOG) clinical centers across the United States (Columbus, New York, Irvine, Philadelphia, Oklahoma, Baltimore). Primary outcome was duration of overall survival. Secondary outcomes included progression-free survival, quality of life and treatment-associated toxicities.

Among women with Stage III ovarian cancer who underwent optimal tumor reductive surgery, those randomized to IV/IP chemotherapy experienced an increased duration of overall survival (67 vs. 50 months, p = 0.03) and a longer progression-free survival (24 vs. 18 months, p = 0.05) compared to those randomized to IV chemotherapy. Compared to women receiving standard IV chemotherapy alone, women in the IV/IP group were more likely to report toxicities including fatigue, pain and neurologic side effects but experienced a similar quality of life 1 year after treatment.

Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. The New England Journal of Medicine. 2006;354(1):34-43.

© 2022 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: © 2 Minute Medicine

Tags: gynecologic oncologyintraperitoneal chemotherapyovarian cancersurvival

New landmark trials, every weekday

The free 2 Minute Medicine Daily Brief: practice-changing studies summarized by physicians, in your inbox.

Your subscription opens securely in a new tab.

More Hematology and oncology Classics

Previous Post

Enteral glutamine does not reduce the time to discharge for severe burns

Next Post

Aggressive hydration does not improve clinical outcomes in acute pancreatitis

Next Post
VEGFR-targeted ultrasound may improve detection of pancreatic cancer

Aggressive hydration does not improve clinical outcomes in acute pancreatitis

Simple score developed to predict increased risk of transthyretin amyloid cardiomyopathy in patients with heart failure with preserved ejection fraction

Positive physician experience in the Pediatric AIDS Corps

Risk of cardiovascular pathology determined using advanced cardiovascular imaging limited by heterogeneity amongst patients with human immunodeficiency virus

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Long-term use of mometasone (Asmanex) in adults with sickle cell disease without formal diagnosis of asthma may worsen disease activity
  • Few patients had ED lumbar CT or MRI within 30 days after low-acuity back-pain radiography at urgent care centers
  • A 34-circular RNA blood signature predicted Alzheimer’s disease progression and improved prediction when combined with pTau217
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • Medical Calculators
    • Clinical Guidelines
    • Physician Pay by Specialty
    • FDA Drug Approvals
    • RVU Search
    • ICD-10 Code Lookup
    • Drug Safety for Breastfeeding/Pregnancy
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
    • NPI Registry Lookup
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.